GP to fund cervical cancer prevention programme
Sunday, 23 March 2008
FE Report
Grameenphone (GP) will fund for the first time in Bangladesh, a pilot programme to prevent cervical cancer among economically disadvantaged young women.
A vaccination programme for prevention of the disease will be administered by Bangladesh Medical College Hospital in collaboration with Bangabandhu Sheikh Mujibur Rahman Medical University and Harvard University, said a press release.
The programme will be jointly conducted by a committee headed by Dr Shaila Khatun.
Under the pilot programme, the HPV vaccination will be administered to 30 economically disadvantaged young women.
"This pilot vaccination programme to prevent cervical cancer among poor young women is a great initiative which has only recently been introduced in some developed countries like the United States, Canada and some European countries and this is perhaps for the first time that it is being planned to be administered in any developing country," said ABMF Karim, chairman of the Oncology Club and adviser of the SAARC Federation of Oncologists.
"As this type of cancer is more prevalent among poor women in our country, it is quite appropriate to target this group," he added.
Cervical cancer is the second most common cancer in women and a leading cause of cancer- related deaths in many developing countries. It affects relatively young women and it is the largest single cause of years of life lost to cancer in the developing world.
The Human Papillona Virus (HPV) accounts for a great majority of all cervical cancers worldwide. The HPV vaccine has recently been found to have the potential to prevent cervical cancer among women.
Grameenphone (GP) will fund for the first time in Bangladesh, a pilot programme to prevent cervical cancer among economically disadvantaged young women.
A vaccination programme for prevention of the disease will be administered by Bangladesh Medical College Hospital in collaboration with Bangabandhu Sheikh Mujibur Rahman Medical University and Harvard University, said a press release.
The programme will be jointly conducted by a committee headed by Dr Shaila Khatun.
Under the pilot programme, the HPV vaccination will be administered to 30 economically disadvantaged young women.
"This pilot vaccination programme to prevent cervical cancer among poor young women is a great initiative which has only recently been introduced in some developed countries like the United States, Canada and some European countries and this is perhaps for the first time that it is being planned to be administered in any developing country," said ABMF Karim, chairman of the Oncology Club and adviser of the SAARC Federation of Oncologists.
"As this type of cancer is more prevalent among poor women in our country, it is quite appropriate to target this group," he added.
Cervical cancer is the second most common cancer in women and a leading cause of cancer- related deaths in many developing countries. It affects relatively young women and it is the largest single cause of years of life lost to cancer in the developing world.
The Human Papillona Virus (HPV) accounts for a great majority of all cervical cancers worldwide. The HPV vaccine has recently been found to have the potential to prevent cervical cancer among women.